15 / 41
KN-059 (COHORTE 1)
Pembrolizumab
FASE II
MSI-H (4%)
No MSI-H (96%)
PD-L1 +
PD-L1 -
Pacientes
7
167
75
58
ORR
IC 95%
57.1%
18.4-90.1
9%
5.1-14.4%
22.7%
13.8-33.8%
8.6%
2.9-19%
KN-059:
pembrolizumab, respuestas
|
|
15 / 41
15 / 41
KN-059 (COHORTE 1)
Pembrolizumab
FASE II
MSI-H (4%)
No MSI-H (96%)
PD-L1 +
PD-L1 -
Pacientes
7
167
75
58
ORR
IC 95%
57.1%
18.4-90.1
9%
5.1-14.4%
22.7%
13.8-33.8%
8.6%
2.9-19%
KN-059:
pembrolizumab, respuestas